From the Department of Nuclear Medicine, Heidelberg University Hospital.
Practice for Oncology, Heidelberg.
Clin Nucl Med. 2021 Oct 1;46(10):842-844. doi: 10.1097/RLU.0000000000003842.
We report a patient with breast cancer (BC) diagnosed in 2009 with metachronous lymph node, liver, and bone metastases. In 2017, colorectal cancer with peritoneal metastases was additionally diagnosed and treated with 8 cycles of capecitabine due to its antitumor activity against both malignancies. At progression of both diseases, FAPI PET/CT demonstrated positive tumor targeting in BC-related metastases and colorectal cancer-related metastases. The patient received an experimental therapy with 90Y-FAPI46. Although there was similar tracer uptake in the PET/CT, the radioligand therapy resulted in mixed response with disappearance of peritoneal metastases but minor efficacy treating the BC-related metastases.
我们报告了一例乳腺癌（BC）患者，该患者于 2009 年被诊断为同时性淋巴结、肝和骨转移。2017 年，另外诊断出结直肠癌伴腹膜转移，由于其对两种恶性肿瘤的抗肿瘤活性，患者接受了 8 个周期的卡培他滨治疗。在两种疾病进展时，FAPI PET/CT 在 BC 相关转移和结直肠癌相关转移中显示出阳性肿瘤靶向。患者接受了 90Y-FAPI46 的实验性治疗。尽管 PET/CT 中摄取类似的示踪剂，但放射性配体治疗的结果是混合反应，腹膜转移消失，但 BC 相关转移的疗效较小。
